Stockreport

Cerevel Therapeutics: Parkinson's Could Be The Issue [Seeking Alpha]

Cerevel Therapeutics Holdings, Inc.  (CERE) 
PDF Concerns may be focused on the Phase 3 treatment Tavapadon for Parkinson's disease. The market expects a 75% chance of the acquisition going through, which could be t [Read more]